Transplant centers participating in the CIBMTR must submit a Post-TED Form for recipients who meet any of the following criteria:

  • Recipient receives a transplant at a United States center designated as a TED-only center.
  • Recipient receives a transplant at a United States center designated as Comprehensive Report Form center, but has been assigned to the TED track by the Form Selection Algorithm.
  • Recipient receives an allogeneic transplant at a United States center designated as Comprehensive Report Form center, but has not consented to participate in research.
  • Recipient receives a transplant at an international center, has consented to participate in research, and has been assigned to the TED track by the Form Selection Algorithm.

The Post-TED fulfills the requirements of the SCTOD for recipients meeting any of the above criteria. For more information regarding the SCTOD, see General Instructions, Stem Cell Therapeutics Outcomes Database.

For more information, including information on the TED and Comprehensive Report Form Selection Algorithm, see Section 1 in the Center Reference Guide.

The Post-TED must be completed at the following time points: 100 days, six months, and annually post-HCT. These forms should be completed as closely to these time points as possible. The structure of the TED Forms is such that each form should fit on a timeline with distinct start and stop dates that do not overlap any other forms, except in the case of a subsequent HCT. The Post-TED is considered past due 120 days after each of these time points.

Subsequent HCT:
If a recipient receives a subsequent HCT between Post-TED time points (100 day, six months, annually), the TED form sequence will start over again with another Pre-TED.

However, if the recipient receives an autologous HCT as a result of a poor graft or graft failure, the TED form sequence will not start over again. Generally this type of infusion (autologous rescue) is used to treat the recipient’s poor graft response, rather than to treat the recipient’s disease.

Contact the CIBMTR Customer Service Center if the subsequent Pre-TED does not come due automatically.

Non-Malignant Diseases
If the HCT being reported was given to treat a non-malignant disease (as reported on the Pre-TED Disease Classification Form {Form 2402}), do not complete the following sections of the Post-TED Form:

  • Q80-102: Disease Assessment at the Time of Best Response to HCT
  • Q103-107: Post-HCT Therapy
  • Q108-118: Relapse or Progression Post-HCT
  • Q119-122: Current Disease Status

Lost to Follow-Up:
Occasionally, centers may lose contact with recipients for a variety of reasons, including the recipient’s moving, changing physicians, or death. If contact with a recipient appears lost, please consider calling the recipient at home or work, sending a letter, communicating with the treating or referring physician, or contacting the hospital billing department. If no documentation exists and several unsuccessful attempts have been made to contact the recipient, they are considered lost to follow-up and the form may be marked as such using the Lost to Follow-Up tool in FormsNet3SM for each reporting period in which no contact exists.

Links to Sections in Manual:
Q1-6: Survival
Q7-13: Subsequent Transplant
Q14-16: Initial ANC Recovery
Q17-18: Initial Platelet Recovery
Q19-44: Graft-Versus-Host Disease
Q45-47: Liver Toxicity Prophylaxis
Q48-49: Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)
Q50-51: Infection
Q52-59: New Malignancy, Lymphoproliferative or Myeloproliferative Disorder
Q60-79: Chimerism Studies
Q80-102: Disease Assessment at the Time of Best Response to HCT
Q103-107: Post-HCT Therapy
Q108-118: Relapse or Progression Post-HCT
Q119-122: Current Disease Status

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
11/20/2020 2450: Post-TED Add Clarification added to question 44 to explain topical non-steroidal agents should not be reported: Indicate whether the recipient is still taking systemic non-steroidal immunosuppressive agents (including PUVA) to treat or prevent acute and / or chronic GVHD on the date of contact. Descriptions of many immunosuppressive agents are included below. Only report systemic non-steroidal immunosuppressive agents and not topical non-steroidal immunosuppressive agents such as Restasis or Protopic.
If the recipient did not receive systemic non-steroidal immunosuppressive agents to treat or prevent acute and / or chronic GVHD during the reporting period, report “not applicable.”
Indicate “not applicable” in any of the following scenarios:
  • The recipient has never received systemic non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD.
  • This form is being completed for a subsequent HCT and the recipient has never received systemic non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD since the start of the preparative regimen for the most recent infusion (or since the date of the most recent infusion if no preparative regimen was given).
  • The recipient stopped taking systemic non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD in a previous reporting period and did not restart non-steroidal immunosuppressive agents (including PUVA) during the current reporting period.
  • The recipient has only received topical non-steroidal immunosuppressive agents (i.e., without ever taking systemic non-steroidal immunosuppressive agents were never administered).
10/23/2020 2450: Post-TED Add Added the following guidance on answering question 63:
Question 63 has been “hidden” in FormsNet3 for the current revision of this form. If an NMDP donor ID had been previously entered, this field will not be hidden and can be edited as needed. However, if an NMDP donor ID has not been entered yet, this field will be hidden and skipped until the form is revised and the question is removed from the form.
9/30/2020 2450: Post-TED Modify The table for time windows for reporting the contact date in Q1 was updated to clarify the 1Y date of contact date should be reported as + 60 days (Day 365 – 425).
8/26/2020 2450: Post-TED Add Blue information box added above question 50 to explain how to report COVID-19 infections when diagnosed after the start of the preparative regimen: Diagnosis of COVID-19 after the start of the preparative regimen: Any COVID-19 infections diagnosed after the start of the preparative regimen should be reported in questions 50 – 51 on the Post-TED (2450) form. An associated Respiratory Virus Post-Infusion Data (2149) form will be generated.
8/20/2020 2450: Post-TED Modify The instructions on how to report disease assessments at the time of best response when a recipient never achieves a CR, progresses, and starts progression therapy were updated in question 84: If the recipient’s best response is “Not in Complete Remission,” report the latest assessment performed during the reporting period. If the recipient never achieved a CR and has started treatment fore relapsed. progressive , or persistent disease (excluding treatment for minimal residual disease), report the most recent latest assessment prior to the initiation of therapy progression. Review example E below.
In addition, example E was added: E. A recipient receives a transplant on 1/1/2015 for NHL in stable disease. During the 100 Day reporting period, a PET / CT was performed on Day 60, confirming stable disease but then on Day 95, another PET / CT was performed and showed progression. As a result, therapy for progression began on Day 100. The best response to HCT for the Day 100 reporting period would be reported as “Not in complete remission – disease detected” and report “Yes,” radiologic assessments were performed with the Day 60 PET / CT as this is the most recent scan prior to progression.
8/19/2020 2450: Post-TED Add Examples 1, 2, and 3 added to question 43 to explain when to use “Yes,” No.” and “Not applicable.”
7/8/2020 2450: Post-TED Remove Updated the instructions on when to report a cellular therapy for relapse, persistent, progressive disease to coincide with the Winter (January) 2020 release: Cellular therapy: Cellular therapy refers to the infusion of human or animal derived cells, which may or may not be modified or processed to achieve a specific composition. Examples include CAR T-cell, NK cell, and mesenchymal cell infusions as well as donor cellular infusions. Indicate “yes” if the recipient received any form of cellular therapy for relapse, persistent, or progressive disease or decreasing / loss of donor chimerism; hematopoietic cell transplantation should not be reported as cellular therapy, as this is captured in questions 7-13 of the Post-TED form. Indicate whether a cellular therapy was infused during the reporting period for relapsed, persistent, or progressive disease and go to question 119.
7/8/2020 2450: Post-TED Add Provided instructions how to report CRISPR testing for COVID-19 for questions 50 – 51: As a result of the global COVID-19 pandemic, the U.S. Food and Drug Administration granted Sherlock Biosciences an emergency use of authorization (EUA) for its COVID-19 diagnostic assay, CRISPR. Although still in its infancy in real-life application, positive results by this method should be reported, even if tandem testing by other method(s) (i.e., PCR) indicate a negative result. If the CRISPR results are unclear, seek physician clarification.
6/3/2020 2450: Post-TED Add The following instructions (red text) were added to question 1 to provide clarification on how to report the contact date for the 1-year reporting period for recipients who receive an allogeneic transplant. If this form is being completed for the 1-year reporting period for a recipient who received an allogeneic transplant, ensure the reported contact date is ≥ Day 365. Review the 1-Year Date of Contact for Allogeneic Transplants instructions below for additional information
5/28/2020 2450: Post-TED Add Added clarification that chromosomal microarrays / chromosomal genomic array should be reported within the FISH assessment data fields.
5/28/2020 2450: Post-TED Removed For question 84, removed instructions allowing chromosomal microarrays / chromosomal genomic array to be reported in the molecular assessment data fields. These assessments should not be reported within the molecular assessment data fields.
5/21/2020 2450: Post-TED Modify Provided clarification on how to report molecular abnormalities identified by other methods of assessment.
5/11/2020 2450: Post-TED Add Added in questions 50-51 to capture information regarding COVID-19 (SARS-CoV-2) infections.
4/7/2020 2450: Post-TED Add For question 41, added guidance on the intent of the question.
4/7/2020 2450: Post-TED Add Added guidance on reporting estimated dates after question 18 (blue information box).
4/6/2020 2450: Post-TED Modify Updated hyperlink in Lost to Follow Up section for the Lost to Follow Up Tool.
4/6/2020 2450: Post-TED Remove Removed sentence in Lost to Follow Up section in introduction – If your center receives documented information that a recipient is alive or dead, the form should be filled out with the recipient survival status.
3/6/2020 2450: Post-TED Remove Removed “reasons other than” in guidance given on Cellular Therapy reporting for question 115 in section Q106-116: Relapse or Progression Post-HCT.
3/6/2020 2450: Post-TED Add Added sentence in second paragraph of Question 106-116: Relapse or Progression Post-HCT regarding scenario where recipient receives a chemotherapy agent that is not listed.
3/5/2020 2450: Post-TED Modify Changed survival status text after Question 1 in section Q1-6: Survival. Instead of completing the POst-TED Form reporting only survival status, the Survival Tool in the CIBMTR Data Management Guide should be used (link to Survival Tool provided after question 1).
3/5/2020 2450: Post-TED Add Added “demonstrated on labial biopsy (labial biopsy not required)” after question 41 in section Graft versus Host Disease.
3/3/2020 2450: Post-TED Modify Added “allogeneic HCT” and “allogeneic HCT recipient whose” in the blue note box at the beginning of Q58-77: Chimerism Studies.
2/19/2020 2450: Post-TED Add Added information on tandem transplant in the introduction to the Disease Assessment at the Time of Best Response to HCT section. Added example to question 78.
2/19/2020 2450: Post-TED Add Added information on tandem transplant in the introduction to the Current Disease Status section. Added examples to question 117.
1/24/2020 2450: Post-TED Modify Version 4 of the 2450: Post-TED section of the Forms Instruction Manual released. Version 4 corresponds to revision 5 of the Form 2450.
Last modified: Nov 20, 2020

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.